Orexigen puts obesity drug development on hold

SymbolPriceChangeARNA1.38-0.03OREX2.12-1.06VVUS8.25-0.29{“s” : “arna,orex,vvus”,”k” : “a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00″,”o” : “”,”j” : “”}

NEW YORK (AP) — The maker of a weight loss drug once seen as a potential blockbuster said it is scrapping its bid for U.S. approval because of “unprecedented” demands by regulators on safety trials.

Orexigen Therapeutics Inc. said Friday that it will focus on developing its drug candidate Contrave and another drug candidate, Empatic, in non-U.S. markets until there is a clear pathway to approval in the U.S. The

Read More from the Article Source: Full Article